Clinical, review 135: The importance of β-cell failure in the development and progression of type 2 diabetes

Journal of Clinical Endocrinology and Metabolism

Volumn 86, Issue 9, 2001, Pages 4047-4058

  Kahn, Steven E ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN;

CELL FUNCTION; DISEASE COURSE; GLUCOSE TOLERANCE; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

ANIMALS; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; HUMANS; ISLETS OF LANGERHANS;

EID: 0034853485     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.86.9.4047     Document Type: Review

References (163)

1. Pathophysiology of type II diabetes mellitus
2. The effect of chronic sulfonylurea therapy on hepatic glucose production in non-insulin-dependent diabetes
3. The acute and chronic effects of sulfonylurea therapy in type II diabetic subjects
4. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
5. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49)
6. UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years
7. Assessing the potential for alpha-glucosidase inhibitors in prediabetic states
8. β-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: The 10-year follow-up of the Belfast Diet Study
9. Plasma insulin responses to oral and intravenous glucose: Studies in normal and diabetic subjects
10. The significance of basal insulin levels in the evaluation of the insulin response to glucose in diabetic and nondiabetic subjects
11. Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests
12. Plasma insulin responses to glucose and tolbutamide of normal weight and obese diabetic and nondiabetic subjects
13. A role for α-adrenergic receptors in abnormal insulin secretion in diabetes mellitus
14. Potentiation of insulin secretory responses by plasma glucose levels in man: Evidence that hyperglycemia in diabetes compensates for impaired glucose potentiation
15. Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus
16. Impaired pulsatile secretion of insulin in relatives of patients with non-insulin-dependent diabetes
17. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus
18. Circulating proinsulin in patients with maturity-onset diabetes
19. Disproportionate elevation of immunoreactive proinsulin in type 2 (non-insulin-dependent) diabetes mellitus and experimental Insulin resistance
20. Serum proinsulin levels at fasting and after oral glucose load in patients with type 2 (non-insulin-dependent) diabetes mellitus
21. Radioimmunoassay may overestimate insulin in non-insulin-dependent diabetics
22. Disproportionately elevated proinsulin in Pima Indians with noninsulin-dependent diabetes mellitus
23. Relationship of proinsulin and insulin with noninsulin-dependent diabetes mellitus and coronary heart disease in Japanese American men: Impact of obesity
24. Release of incompletely processed proinsulin is the cause of the disproportionate proinsulinemia of NIDDM
25. Decrease of stimulated amylin release precedes impairment of insulin secretion in type II diabetes
26. Plasma islet amyloid polypeptide levels in obesity, impaired glucose tolerance and non-insulin-dependent diabetes mellitus
27. Reduced amylin release is a characteristic of impaired glucose tolerance and type 2 diabetes in Japanese Americans
28. Plasma insulin concentrations in nondiabetic and early diabetic subjects: Determinations by a new sensitive immunoassay technic
29. Carbohydrate metabolism in hyperadrenocorticism
30. A new phase of insulin secretion: How will it contribute to our understanding of β-cell function?
31. Identification of the docked granule pool responsible for the first phase of glucose-stimulated insulin secretion
32. Newly synthesized proinsulin/insulin and stored insulin are released from pancreatic B cells predominantly via a regulated, rather than a constitutive, pathway
33. Kinetics of proinsulin conversion in human islets
34. β-cells in type II diabetes mellitus
35. Paradoxical inhibition of insulin secretion by glucose in human diabetes mellitus
36. Non-insulin-dependent diabetes mellitus - A genetically programmed failure of the beta cell to compensate for insulin resistance
37. Mechanisms of impaired acute insulin release in adult onset diabetes: Studies with isoproterenol and secretin
38. Early insulin responses to glucose and to tolbutamide in maturity-onset diabetes
39. Potentiation of insulin release by glucose in man. II. Role of the insulin response, and enhancement of stimuli other than glucose
40. Disproportionately elevated proinsulin levels reflect the degree of impaired B-cell secretory capacity in patients with non-insulin dependent diabetes mellitus
41. Abnormal glucose regulation of insulin secretion in models of reduced B-cell mass
42. Reduction of glycemic potentiation: A sensitive indicator of β-cell loss in partially pancreatectomized dogs
43. Control of pulsatile insulin secretion in man
44. Oscillatory insulin secretion in perifused isolate rat islets
45. Brief, irregular oscillations of basal plasma insulin and glucose concentrations in diabetic man
46. Pulsatile insulin has greater hypoglycemic effect than continuous delivery
47. Effects of prolonged pulsatile hyperinsulinemia in humans. Enhancement of insulin sensitivity
48. Twenty-four-hour profiles and patterns of insulin secretion in normal and obese subjects
49. Lack of control by glucose of ultradian insulin secretory oscillations in impaired glucose tolerance and in non-insulin-dependent diabetes mellitus
50. Structural domains and molecular lifestyles of insulin and its precursors in the pancreatic β cell
51. Identification of a human insulinoma cDNA encoding a novel mammalian protein structurally related to the yeast dibasic processing protease Kex2
52. Identification of a cDNA encoding a second putative prohormone convertase related to PC2 in AtT20 cells and islets of Langerhans
53. The effects of biosynthetic human proinsulin on carbohydrate metabolism in non-insulin-dependent diabetes mellitus
54. Hyperproinsulinemia and amyloid in NIDDM: Clues to etiology of islet β-cell dysfunction?
55. What β-cell defect could lead to hyperproinsulinemia in NIDDM? Some clues from recent advances made in understanding the proinsulin-processing mechanism
56. Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islets
57. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients
58. Co-localization of islet amyloid polypeptide and insulin in the B cell secretory granules of the human pancreatic islets
59. Evidence of cosecretion of islet amyloid polypeptide and insulin by β-cells
60. Pancreatic amylin and calcitonin gene-related peptide cause resistance to insulin in skeletal muscle in vitro
61. Inhibitory effect of rat amylin on the insulin responses to glucose and arginine in the perfused rat pancreas
62. Amylin and the amylin gene: Structure, function and relationship to islet amyloid and to diabetes mellitus
63. Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin
64. Relationship between fasting plasma insulin level and resistance to insulin-mediated glucose uptake in normal and diabetic subjects
65. Quantification of the relationship between insulin sensitivity and B-cell function in human subjects. Evidence for a hyperbolic function
66. Basal and stimulated hyperinsulinism: Reversible metabolic sequelae of obesity
67. Quantitative study of insulin secretion and clearance in normal and obese subjects
68. Relationship of islet function to insulin action in human obesity
69. Physiologic evaluation of factors controlling glucose tolerance in man: Measurement of insulin sensitivity and β-cell glucose sensitivity from the response to intravenous glucose
70. Toward physiological understanding of glucose tolerance: Minimal-model approach
71. Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus
72. Regulation of B-cell function in vivo: From health to disease
73. Reduced β-cell compensation to the insulin resistance associated with obesity in members of Caucasian familial type 2 diabetic kindreds
74. Insulin resistance and impaired insulin secretion in subjects with histories of gestational diabetes mellitus
75. Defects in insulin secretion and action in women with a history of gestational diabetes
76. Antepartum predictors of the development of type 2 diabetes in Latino women 11-26 months after pregnancies complicated by gestational diabetes
77. β-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome
78. Pathogenesis of age-related glucose intolerance in man: Insulin resistance and decreased β-cell function
79. Effect of exercise on insulin action, glucose tolerance and insulin secretion in aging
80. Exercise training delineates the importance of B-cell dysfunction to the glucose intolerance of human aging
81. Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance
82. Heritability of pancreatic beta-cell function among nondiabetic members of Caucasian familial type 2 diabetic kindreds
83. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus
84. Increased insulin concentrations in nondiabetic offspring of diabetic parents
85. Impaired glucose tolerance as a disorder of insulin action. Longitudinal and cross-sectional studies in Pima Indians
86. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents
87. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: Results of a 25-year follow-up study
88. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus
89. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians
90. Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: Problems and prospects
91. Earlier appearance of impaired insulin secretion than of visceral adiposity in the pathogenesis of NIDDM: 5-Year follow-up of initially nondiabetic Japanese-American men
92. Decreased insulin secretion and increased insulin resistance are independently related to the 7-year risk of NIDDM in Mexican-Americans
93. Pancreatic beta-cell dysfunction as the primary, genetic lesion in NIDDM. Evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative
94. Failure to adequately adapt reduced insulin sensitivity with increased insulin secretion in women with impaired glucose tolerance
95. The relation of proinsulin, insulin, and proinsulin-to-insulin ratio to insulin sensitivity and acute insulin response in normoglycemic subjects
96. Proinsulin as a marker for the development of NIDDM in Japanese-American men
97. Effects of arginine on the secretion of insulin and islet amyloid polypeptide in humans
98. Human aging is associated with parallel reductions in insulin and amylin release
99. Increased β-cell secretory demand is not the simple explanation for inefficient proinsulin processing and islet amyloid formation in type 2 diabetes
100. Non-diabetic first degree relatives of individuals with type 2 diabetes have diminished insulin and amylin release as markers of islet B-cell function
101. Pathogenesis of NIDDM. A balanced overview
102. Glucose toxicity
103. Differentiating glucose toxicity from glucose desensitization: A new message from the insulin gene
104. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications
105. Islet amyloid, islet-amyloid polypeptide, and diabetes mellitus
106. Islet amyloid: A long-recognized but underappreciated pathological feature of type 2 diabetes
107. Mechanisms of insulin resistance in human obesity: Evidence for receptor and postreceptor defects
108. Risk factors for non-insulin-dependent diabetes
109. Increased β-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance
110. Effect of insulin resistance and hyperglycemia on proinsulin release in a primate model of diabetes mellitus
111. Partial pancreatectomy in the rat and subsequent defect in glucose-induced insulin release
112. β-cell dysfunction induced by chronic hyperglycemia. Current ideas on mechanism of impaired glucose-induced insulin secretion
113. The reduction of insulin gene transcription in HIT-T15 β cells chronically exposed to high glucose concentration is associated with the loss of RIPE3bl and STF-1 transcription factor expression
114. The homeodomain protein IDX-1 increases after an early burst of proliferation during pancreatic regeneration
115. Short-term hyperglycemia and hyperinsulinemia improve insulin action but do not alter glucose action in normal humans
116. Insulin secretion and clearance during low-dose graded glucose infusion
117. Adaptation of B and A cell function during prolonged glucose infusion in human subjects
118. Maladaptation of beta cell function to hyperglycemia in noninsulin-dependent diabetes mellitus
119. Proinsulin, C-peptide, and insulin in normal subjects during an 8-h hyperglycemic clamp
120. Regulation by glucose of the biosynthesis of PC2, PC3 and proinsulin in (ob/ob) mouse islets of Langerhans
121. Glucose-regulated translational control of proinsulin biosynthesis with that of the proinsulin endopeptidases PC2 and PC3 in the insulin- producing MIN6 cell line
122. Direct antidiabetic effect of leptin through triglyceride depletion of tissues
123. Endocytosis of low-density lipoprotein by human pancreatic beta cells and uptake in lipid-storing vesicles, which increase with age
124. Diet of second-generation Japanese-American men with and without non-insulin-dependent diabetes
125. The role of dietary carbohydrate in the decreased glucose tolerance of the elderly
126. Insulin resistance and β-cell dysfunction in aging: The importance of dietary carbohydrate
127. Improved glucose tolerance with high carbohydrate feeding in mild diabetes
128. Defective glucose-stimulated insulin release from perifused islets of C57BL/6J mice
129. Reduced β-cell function contributes to impaired glucose tolerance in dogs made obese by high-fat feeding
130. Longitudinal compensation for fat-induced insulin resistance includes reduced insulin clearance and enhanced β-cell response
131. The regulation of adipose tissue distribution in humans
132. A 48-hour lipid infusion in the rat time-dependently inhibits glucose-induced insulin secretion and B cell oxidation through a process likely coupled to fatty acid oxidation
133. Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle
134. Long term exposure to fatty acids and ketones inhibits B-cell functions in human pancreatic islets of Langerhans
135. Lipotoxicity of the pancreatic β-cell is associated with glucose-dependent esterification of fatty acids into neutral lipids
136. Effects of a 48-h fat infusion on insulin secretion and glucose utilization
137. Leptin rapidly suppresses insulin release from insulinoma cells, rat and human islets and, in vivo, in mice
138. Inhibition of insulin secretion by leptin in normal rodent islets of Langerhans
139. Leptin suppression of insulin secretion and gene expression in human pancreatic islets: Implications for the development of adipogenic diabetes mellitus
140. TNF-alpha inhibits glucose-induced insulin secretion in a pancreatic β-cell line (INS-l)
141. Tumor necrosis factor-α and interferon-γ inhibit insulin secretion and cause DNA damage in unweaned-rat islets. Extent of nitric oxide involvement
142. Differential volumetry of A, B, and D cells in the pancreatic islets of diabetic and nondiabetic subjects
143. Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited
144. The influence of amyloid deposits on the islet volume in maturity onset diabetes mellitus
145. Glucose and tolbutamide induce apoptosis in pancreatic beta-cells. A process dependent on intracellular Ca2+ concentration
146. Fatty acid-induced beta cell apoptosis: A link between obesity and diabetes
147. The relation of diabetes mellitus to lesions of the pancreas. Hyaline degeneration of the islets of Langerhans
148. Longitudinal studies on the development of diabetes in individual Macaca nigra
149. Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide
150. vy/a mice expressing human islet amyloid polypeptide
151. Extensive islet amyloid formation is induced by development of Type II diabetes mellitus and contributes to its progression: Pathogenesis of diabetes in a mouse model
152. Oophorectomy promotes islet amyloid formation in a transgenic mouse model of type 2 diabetes
153. β-cell glucokinase deficiency and hyperglycemia are associated with reduced islet amyloid deposition in a mouse model of type 2 diabetes
154. High-fat, low-carbohydrate diet and the etiology of non-insulin- dependent diabetes mellitus: The San Luis Valley Diabetes Study
155. A prospective study of postmenopausal estrogen therapy and subsequent incidence of non-insulin-dependent diabetes mellitus
156. Islet amyloid polypeptide: Pinpointing amino acid residues linked to amyloid fibril formation
157. Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus
158. The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles
159. The hormone resistin links obesity to diabetes
160. Insulin secretory defect in Zucker fa/fa rats is improved by ameliorating insulin resistance
161. A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat
162. Minimal model analysis of intravenous glucose tolerance test-derived insulin sensitivity in diabetic subjects
163. Regulation of insulin secretion in vivo